SI-BONE Reports Q3 2026 Revenue Growth Driven by Increased Procedure Volume and Physician Adoption
SI-BONE (SIBN) reported third-quarter 2026 worldwide revenue of $55.7 million, a 14.5% increase year-over-year. This growth was primarily fueled by a 19.5% surge in U.S. procedure volume and a significant expansion of the company's physician base, which reached a record 1,770 active users. While lower average selling prices due to shifts toward ambulatory surgery centers impacted margins slightly, the company saw improved operating leverage. The company also highlighted strategic product launches, including iFuse Granite Onyx, which expands its total addressable market to approximately $5 billion. Despite a net loss of $3.6 million, SI-BONE showed significant improvement in Adjusted EBITDA and operating cash flow compared to the previous year. Management provided full-year 2026 revenue guidance of $231 million to $233 million, reflecting continued confidence in market expansion.
Tickers: $SIBN
Topics: Adjusted EBITDA Net Loss Improvement Procedure Volume Revenue Growth